- Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
- Compugen Appoints David Silberman as Chief Financial Officer
- Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
- Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
- Compugen to Participate in Two Upcoming Investor Conferences
- Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
- Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
- Compugen Reports Fourth Quarter and Full Year 2023 Results
- Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
More ▼
Key statistics
On Thursday, Compugen Ltd (CGEN:TLV) closed at 795.30, -32.31% below its 52-week high of 1,175.00, set on Mar 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 802.00 |
---|---|
High | 824.00 |
Low | 792.10 |
Bid | 796.00 |
Offer | 799.20 |
Previous close | 798.30 |
Average volume | 131.23k |
---|---|
Shares outstanding | 89.53m |
Free float | 84.72m |
P/E (TTM) | -- |
Market cap | 675.59m ILS |
EPS (TTM) | -0.8026 ILS |
Data delayed at least 20 minutes, as of May 16 2024 15:24 BST.
More ▼